Mechanism of KDM5C-Mediated H3K4me3 Demethylation of HOXC-AS3 in the Proliferation of Colorectal Cancer Cells
- PMID: 40629546
- DOI: 10.1002/kjm2.70068
Mechanism of KDM5C-Mediated H3K4me3 Demethylation of HOXC-AS3 in the Proliferation of Colorectal Cancer Cells
Abstract
Colorectal cancer (CRC) ranks as the third most prevalent malignancy and the second leading cause of cancer-related mortality worldwide. This study explored the role of lysine-specific histone demethylase 5C (KDM5C) in CRC progression. Expression levels of KDM5C, HOXC-AS3, and discs large MAGUK scaffold protein 4 (DLG4) were evaluated. Following the KDM5C knockdown, cell proliferation assays were conducted. The recruitment of KDM5C and histone H3 lysine 4 tri-methylation (H3K4me3) to the HOXC-AS3 promoter region was investigated. Furthermore, the subcellular distribution of HOXC-AS3 was assessed using nuclear-cytoplasmic fractionation and RNA fluorescence in situ hybridization (RNA-FISH). The interactions between HOXC-AS3, YTH domain-containing protein 1 (YTHDC1), and DLG4 were detected. The stability of DLG4 mRNA was evaluated, and the functional roles of HOXC-AS3 and DLG4 in CRC cells were examined through combined experimental analyses. KDM5C expression was elevated in CRC cells, whereas HOXC-AS3 and DLG4 levels were notably reduced. Silencing KDM5C resulted in suppressed cell proliferation. Mechanistically, KDM5C inhibited HOXC-AS3 expression by demethylating H3K4me3 at its promoter. HOXC-AS3 promoted DLG4 mRNA stability by recruiting the RNA-binding protein YTHDC1. Combined experimental results indicated that overexpression of HOXC-AS3 or DLG4 reduced the inhibitory effect of KDM5C downregulation on CRC cells. In conclusion, KDM5C promotes CRC cell proliferation by demethylating H3K4me3, repressing HOXC-AS3 expression. The reduced HOXC-AS3 levels impair the recruitment of YTHDC1, leading to decreased DLG4 expression.
Keywords: DLG4; HOXC‐AS3; KDM5C; YTHDC1; colorectal cancer.
© 2025 The Author(s). The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical University.
Similar articles
-
BMSC derived EVs inhibit colorectal Cancer progression by transporting MAGI2-AS3 or something similar.Cell Signal. 2024 Sep;121:111235. doi: 10.1016/j.cellsig.2024.111235. Epub 2024 May 26. Cell Signal. 2024. PMID: 38806109
-
SETD1A-mediated H3K4me3 methylation upregulates lncRNA HOXC-AS3 and the binding of HOXC-AS3 to EP300 and increases EP300 stability to suppress the ferroptosis of NSCLC cells.Thorac Cancer. 2023 Sep;14(25):2579-2590. doi: 10.1111/1759-7714.15037. Epub 2023 Aug 7. Thorac Cancer. 2023. PMID: 37548102 Free PMC article.
-
Long non-coding RNA HOXC-AS1 promotes the malignancy by sponging miR-195-5p with ANLN in esophageal cancer.Cytotechnology. 2025 Apr;77(2):68. doi: 10.1007/s10616-025-00711-z. Epub 2025 Feb 24. Cytotechnology. 2025. PMID: 40012926
-
Strategies for detecting colon cancer in patients with inflammatory bowel disease.Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD000279. doi: 10.1002/14651858.CD000279.pub4. Cochrane Database Syst Rev. 2017. PMID: 28922695 Free PMC article.
-
Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.Health Technol Assess. 2017 Sep;21(51):1-238. doi: 10.3310/hta21510. Health Technol Assess. 2017. PMID: 28895526 Free PMC article.
References
-
- Y. Xi and P. Xu, “Global Colorectal Cancer Burden in 2020 and Projections to 2040,” Translational Oncology 14, no. 10 (2021): 101174.
-
- V. A. Ionescu, G. Gheorghe, N. Bacalbasa, A. L. Chiotoroiu, and C. Diaconu, “Colorectal Cancer: From Risk Factors to Oncogenesis,” Medicina 59, no. 9 (2023): 1646.
-
- E. Dekker, P. J. Tanis, J. L. A. Vleugels, P. M. Kasi, and M. B. Wallace, “Colorectal cancer,” Lancet 394, no. 10207 (2019): 1467–1480.
-
- L. H. Biller and D. Schrag, “Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review,” JAMA 325, no. 7 (2021): 669–685.
-
- Y. Ohguchi and H. Ohguchi, “Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?,” Cancers 14, no. 13 (2022): 3270.
LinkOut - more resources
Full Text Sources
Research Materials